1
. Sphingolipids also regulate vari ous biological processes such as growth, proliferation, migration, invasion and/or metastasis by controlling sig nalling functions within the cancer cell signal transduc tion network 2, 3 . For example, the generation of cera mide and sphingosine is induced by chemotherapy, radiation and/or oxidative stress, and these sphingolipids mediate cell death, senescence and/or cell cycle arrest 4 . However, metabolic conversion of ceramide to sphingosine1 phosphate (S1P), sphingomyelin or glucosylceramide has antiapoptotic and prosurvival roles 5, 6 . Over the past few decades, nearly all the major enzymes involved in sphingolipid metabolism have been identified and cloned, which has provided data that reveal that the abundance of sphingolipids is highly regulated by these metabolic enzymes, the altered expression or activ ity of which has key roles in the regu lation of cancer signalling and/or treatment. These studies have led to clinical trials in patients with various types of tumours evaluating the potential of therapeutic strategies tar geting the enzymes that catabolize ceramide or that generate S1P. This Review discusses the recent mechanistic and clinical studies that have had a major influence in the understanding of the role of sphingolipids in various aspects of cancer biology and therapeutics. Specifically, mechanisms of ceramidemediated cell death and S1Pdependent tumour growth, proliferation and metas tasis are highlighted, with particular attention given to clinical cancer therapy, tumour immunology and immunotherapy. Finally, current and emerging thera peutic strategies targeting enzymes involved in sphingo lipid metabolism and/or signalling for cancer therapy are presented. functions 7, 8 . Multiple signalling nodes in sphingo lipid metabolism, including sphingolipids, meta bolic enzymes and/or receptors, represent novel therapeu tic targets for the development of novel anticancer intervention strategies.
Sphingolipid structure and metabolism
Ceramide consists of a sphingosine longchain base (LCB) and an amidelinked fatty acyl chain that varies from 14 to 26 carbons (C) in length 1, 2 
Endogenous ceramides are synthesized via the de novo pathway, which begins with the condensation of serine and palmitoylCoA by serine palmitoyltransferase (SPT) to form 3ketosphinganine, which is reduced to sphin ganine by 3ketosphinganine reductase, leading to the synthesis of dihydroceramide by (dihydro)cera mide synthases 9, 10 -which have been referred to simply as ceramide synthases (CERS1-6) 11 , as they are rate limiting enzymes for the synthesis of endogenous ceramides after dihydroceramide desaturation (FIG. 1) . Dihydroceramide is desaturated to yield ceramide by dihydroceramide desaturase (DES; also known as DEGS1) via insertion of a double bond between C4 and C5 in the LCB ( generating d18:1 LCB) 12 .
Box 1 | Sphingolipidomics and cancer
Ceramide is composed of a sphingosine long-chain base (LCB) containing 18 carbons (d18), which is amide-linked to a fatty acyl chain containing variable numbers of carbons, ranging from 14 to 26. The de novo synthesis of ceramide by (dihydro)ceramide synthases (CERS1-6) generates ceramide molecules with different fatty acyl chains that have distinct biological roles in cancer cells, possibly due to differential subcellular localization and/or trafficking in cells 1 . Moreover, recent data have suggested that in addition to the more abundant d18 LCB, ceramides that are generated endogenously via CERS1-6 can include an LCB with 16 or 20 carbons 174 , which might also have distinct biological roles in cancer. Thus, major bioactive sphingolipid molecules -including ceramides and other distinct sphingolipids, such as α-hydroxyceramides and 1-O-acyl-ceramides 173 -can have distinct fatty acyl chain lengths (as well as distinct LCB sphingosine backbones 174 ). The chemical structures of major sphingolipids are shown below. The global measurement of these distinct sphingolipids and ceramides with different fatty acyl chain lengths or LCBs in cancer cells, tumour tissues or plasma is performed by quantitative sphingolipidomics using mass spectrometry-based assays 171, 172 . The tissue localization of these distinct ceramides or sphingolipids can also be visualized using matrixassisted laser desorption ionization (MALDI) imaging mass spectrometry 153 . Overall, quantitative measurements of sphingolipids by sphingolipidomics coupled with sub-tissue localization using MALDI imaging provide mechanistic and therapeutic insights into the roles of these bioactive molecules in cancer biology and therapy. Nature Reviews | Cancer CERS1-6 are specialized for ceramide synthe sis with different fatty acyl chain lengths: CERS1 and CERS4 generate C18-20 ceramides, CERS5 and CERS6 generate C14-16 ceramides, and CERS2 selec tively generates C22-24 ceramides 12, 13 
. CERS3 mediates the synthesis of verylongchain C28-32 ceramides with polyunsaturated (4-6 double bonds) fatty acid resi dues, which are specifically expressed in testes and skin tissues 14 . Ceramide is also generated by sphingomyelin ases (SMases), which mediate sphingo myelin hydrolysis, or by the cerebrosidase enzymes glucosylceramidase (GlcCDase) and galactosylcerami dase (GCDase) (FIG. 1) , which catalyse glucosylceramide and/or galactosyl ceramide breakdown to ceramide [1] [2] [3] [4] . The salvage pathway for ceramide generation utilizes recycling of sphingosine as a substrate for CERS1-6 Nature Reviews | Cancer Ceramide is the central molecule in sphingolipid metabolism and can be synthesized de novo (dark blue boxes) by the functions of serine palmitoyltransferase (SPT), 3-ketosphinganine reductase, (dihydro)ceramide synthases (CERS1-6) and dihydroceramide desaturase (DES). Ceramide can also be generated by the hydrolysis of complex sphingolipids such as sphingomyelin (SM) by the action of sphingomyelinases (SMases) (purple box). Conversion of sphingosine to ceramide is catalysed by the salvage pathway (red boxes) via CERS1-6, the same enzymes involved in de novo ceramide synthesis. Ceramide is metabolized to generate sphingosine-1-phosphate (S1P) by the functions of ceramidases (CDases) and sphingosine kinase 1 (SPHK1) and SPHK2. S1P is further hydrolysed by S1P lyase to exit the sphingolipid metabolic cycle. The metabolism of ceramide to generate complex sphingolipids such as glycosphingolipids or gangliosides requires the synthesis of glucosylceramide (GlcCer) by glucosylceramide synthase (GCS) (green box), which is a precursor for the synthesis of complex sphingolipids (dotted arrows). Sphingomyelin synthase (SMS) enzymes convert ceramide to SM via insertion of a choline moiety into ceramide as a head group using phosphatidylcholine (PC) as a donor, yielding free diacylglycerol (DAG), and ceramide kinase (CERK) converts ceramide to ceramide-1-phosphate (C1P) (orange boxes 
Glycosphingolipids
A subtype of glycolipids that contain amino alcohol sphingosine, which include cerebrosides, gangliosides and globosides.
Lysosomal storage diseases
A group of inherited metabolic disorders that result from defective lysosomal function and are mainly associated with accumulation of sphingolipids and/or glycosphingolipids.
Pheochromocytoma
A rare tumour of the adrenal gland. (FIG. 1) ; the salvage pathway also involves the recycling of exogenous shortchain C2-6 ceramides for the gen eration of endogenous longchain C14-26 ceramides, which exert various signalling functions in cancer cells, such as inhibition of Myc protooncogene protein (MYC) and telomerase 15 . CERK 16 and SMS 17 convert ceramide to ceramide1 phosphate (C1P) and sphingomyelin, respectively (FIG. 1) . Ceramide is also utilized as a precursor for the genera tion of glucosylceramide by GCS 18 . Glucosylceramide is then transported from the early Golgi to the distal Golgi compartments by phosphatidylinositol4phosphate adaptor protein 2 (FAPP2; also known as PLEKHA8) for the synthesis of lactosylceramide and subsequently complex glycosphingolipids, which determine the lipid composition of the plasma membrane 19 . Nonvesicular C1P trafficking is regulated by glycolipid transfer pro tein domain containing protein 1 (GLTPD1; also known as CPTP), which has been shown to induce prosta glandin signalling and inflammation in A549 human lung cancer cells 20 . Ceramide is hydrolysed by ceramidases (CDases) to yield sphingosine, which is phosphorylated by SPHK1 (also known as SK1) or SPHK2 (also known as SK2) to generate S1P, which engages with five specific G protein coupled receptors (GPCRs), S1PR1-5 (also known as S1P [1] [2] [3] [4] [5] ), in an autocrine or paracrine manner to elicit prosurvival signalling in various cancer cells 21 . S1P is rapidly metabolized by S1P phosphatase (SGPP) 22 to sphingosine or by S1P lyase 1 (SPL; also known as SGPL1) 23 to yield ethanolamine1phosphate and hexadecanol (C16 fatty aldehyde) (FIG. 1) .
The clinical relevance of sphingolipid metabolism has been established, as mutations in key metabolic enzymes are associated with lysosomal storage diseases such as Gaucher disease (glucocerebrosidase or GlcCDase defi ciency), Farber disease (AC mutations), Krabbe dis ease (GCDase deficiency) and Niemann-Pick disease (mutations in SMPD1, which encodes acid sphingo myelinase (ASMase)), owing to aberrant accumulation of sphingolipids; thus, they are also referred to as sphin golipidoses 24 (FIG. 1) . Moreover, some of these metabolic disorders are linked to cancer development; for example, patients with Gaucher disease have an increased risk of developing myeloma 25 .
Sphingolipid enzymes and cancer
The abundance of sphingolipid molecules is highly regu lated by metabolic enzymes, the altered expression or activity of which has key roles in the induction of cancer cell death or survival (FIG. 1; TABLE 1 ).
SPT. Mammalian trimeric SPT consists of two large sub units (serine palmitoyltransferase 1 (SPTLC1), SPTLC2 or SPTLC3) and a small subunit (SPT small subunit A (SPTSSA) or SPTSSB) and is localized in the endoplas mic reticulum (ER) 26 . Specific missense mutations in the human SPTLC1 gene, which result in the accumu lation of 1deoxysphingoid bases owing to the utiliza tion of lalanine instead of lserine as a substrate by the mutant SPT, are associated with hereditary sensory neuropathy type I (REF. 27 ). SPTmediated elevation of cellular 1deoxysphingoid base levels has been linked to paclitaxelinduced peripheral neuropathy in cell cul ture models as well as in serum samples from patients with breast cancer who received paclitaxel treatment 28 , which presents a major doselimiting toxicity for pacli taxel treatment in patients with breast cancer. The metabolic switch from SPTdependent generation of 1deoxysphingoid bases to conventional sphingolipids, such as (dihydro)sphingosine and/or ceramide, by use of lserine might be a potential therapeutic intervention to alleviate paclitaxelinduced neurotoxicity in various cancer settings 27, 28 . However, this strategy requires test ing in future clinical trials. In addition, the ORM pro teins (encoded by ORMDL genes in humans, including ORMDL3) have been identified as key suppressors of SPT function that limit cellular sphingolipid levels in yeast and mammalian cells, including HEK293 and HeLa cells 29, 30 . However, it remains unknown whether ORMDLs have roles in the regulation of cancer cell sur vival in the absence and/or presence of various cellular stress stimuli, such as chemotherapy.
CERS1-6.
The discovery and cloning of CERS1-6 (REFS 9-11) were key to understanding the roles of cera mides with different fatty acyl chain lengths in cancer cell signalling. For example, CERS1 expression was found to be repressed in head and neck cancer cells by histone deacetylase 1 (HDAC1) and miR5745p, there fore inhibiting C18 ceramide generation 31 . In addition, CERS1generated C18 ceramide induced cell death and tumour suppression in cell culture and xenograft mouse models of head and neck squamous cell carcinoma (HNSCC) 32, 33 . Approximately 50% of mice with germline loss of Cers2, which is involved in reduction of long chain (C22-24) ceramides, developed pheochromocytoma owing to possible defects in apoptosis 34 . Moreover, CERS6generated C16 ceramide was identified as a transcriptional target of p53 that is activated by non genotoxic folate stress to induce cell death in p53 wild type human lung cancer cells 35 . CERS6generated C16 ceramide was also shown to increase tumour necrosis factor related apoptosisinducing ligand (TRAIL) sensi tivity by inducing nuclear translocation of caspase 3 in colon cancer cells 36 . Moreover, CERS6generated C16 cera mide induced BAXmediated apoptosis in response to irradiation in HeLa cells 37 . The mitochondria associated antiapoptotic protein Bcl2like protein 13 (BCL2L13) directly inhibited ceramide synthesis in glioblastoma cell lines and xenograft tumours in mice by binding to CERS2 and CERS6, therefore blocking their homo dimerization and heterodimerization 38 . In addition to its apoptotic roles, increased levels of CERS6generated C16 ceramide were detected in lung and oral cancer tissues compared with matched non cancerous tissues 39, 40 . Unexpectedly, CERS6generated C16 ceramide was found to protect the integrity of the ER and Golgi membranes in HNSCC cells; downregula tion of CERS6 altered trafficking of activating transcrip tion factor 6 (ATF6) and induced its aberrant activation, resulting in ERstressmediated HNSCC cell death 41, 42 .
Overall, these studies support the notion that CERS generated ceramides with different fatty acyl chains have distinct roles in inducing cancer cell death and survival, which are dependent on the context and/or tissue or cell type.
DES.
For many decades, exogenous dihydroceramide was considered an inactive sphingolipid molecule pos sibly owing to its poor solubility. However, knockdown of DES or pharmacological inhibition using fenretinide or C8cyclopropenylceramide was reported to increase the accumulation of endogenous dihydroceramides, delaying the G1-S cell cycle transition in neuroblastoma cells 43 . These data suggest that endogenous dihydro ceramide has signalling roles that inhibit cancer cell growth without inducing apoptosis. However, whether therapeutic targeting of DES inhibits apoptosis owing to a decrease in ceramide generation remains unknown.
SMases. Ceramide is also generated by the hydrolysis of sphingomyelin by SMases. Based on their pH dependent optimal activity, there are three types of SMases: acid, neutral and alkaline 44 . Induction of ASMase 44, 45 expres sion increased ceramide generation, resulting in apop totic cell death in human lymphoblasts, both in culture and in mice 46 . Interestingly, Smpd1 −/− mice were pro tected from lung and spleen metastasis by melanoma cells, and transplantation of Smpd1 wildtype mouse platelets to Smpd1 −/− mice reactivated tumour metasta sis 47 . Mechanistically, melanoma cells exhibited increased AC, acid ceramidase; AML, acute myeloid leukaemia; ASMase, acid sphingomyelinase; C1P, ceramide-1-phosphate; C8-CPC, C8-cyclopropenylceramide; CERK, ceramide kinase; CERS, ceramide synthase; CERT, ceramide transfer protein; CHC, 3-chloro-8β-hydroxycarapin-3,8-hemiacetal; DES, dihydroceramide desaturase; ER, endoplasmic reticulum; FB1, fumonisin B1; GCS, glucosylceramide synthase; GlcCer, glucosylceramide; GVHD, graft-versus-host disease; HDAC, histone deacetylase; NSMase, neutral sphingomyelinase; PDMP, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol; PPMP, 1-phenyl-2-palmitoyl-3-morpholino-1-propanol; S1P, sphingosine-1-phosphate; SPHK, sphingosine kinase; SPL, S1P lyase 1; SPT, serine palmitoyltransferase; THI, tetrahydroxybutylimidazole.
platelet secretory ASMase activity, which induced C16 ceramide formation and led to activation and clustering of α5β1 integrin on melanoma cells, thereby promot ing cancer cell adhesion and metastasis 47 . These data suggest that although induction of ASMase in cancer cells results in apoptosis, systemic ASMase activation in platelets leads to increased melanoma metastasis, high lighting the importance of celltypespecific expression of enzymes involved in ceramide signalling in inducing cell death versus increasing survival and/or migration, similar to CERS6-C16 ceramide signalling in lung cancer ( apoptotic) 35 versus HNSCC (survival) 41 cells. In addition to the roles of neutral sphingomyelin ase 2 (NSMase2; also known as SMPD3) in indu cing ceramidedependent cell cycle arrest 48 , it has been shown that exosome release from cells is dependent on NSMase2generated ceramide, which was necessary for intraendosomal membrane transport of multivesic ular endosomes that are then secreted as exosomes 49 . However, whether NSMase2dependent ceramide enriched exosomes influence cancer cell cycle arrest remains to be determined.
In addition, alkaline sphingomyelinase (AlkSMase; also known as NPP7) deficiency resulted in increased tumour size and number in mouse models of colon cancer induced by azoxymethane (AOM) and dextran sulfate sodium, possibly owing to reduced ceramide generation 50 . Collectively, these data support the hypothesis that the hydrolysis of sphingomyelin by SMases generates ceramide, which mediates cancer cell death, growth arrest and/or tumour suppression.
SMS and CERT.
The metabolic conversion of ceramide to sphingomyelin, which occurs mainly in the Golgi as well as in the plasma membrane, is catalysed by sphingo myelin synthase 1 (SMS1) localized in the Golgi and SMS2 localized in the Golgi and plasma membrane 17, 51 . The synthesis of sphingomyelin is regulated by cera mide transport from the ER to the Golgi by ceramide transfer protein (CERT; also known as COL4A3BP) via a nonvesicular mechanism 52, 53 . Loss of CERT expres sion was reported to augment epidermal growth factor receptor (EGFR) signalling in triple negative breast cancer (TNBC) cells through alterations in sphingo myelin levels at the plasma membrane 54 . Moreover, CERT knockdown sensitized ovarian cancer, colorectal cancer (CRC) and/or HER2positive breast cancer cells to paclitaxelinduced cell death through induction of ceramidemediated ER stress or lysosomeassociated membrane glycoprotein 2 (LAMP2)dependent auto phagic flux 55 . Pharmacological inhibition of CERT using 3chloro8βhydroxycarapin3,8hemiacetal (CHC) was also reported to effectively induce ceramidedependent HeLa cell death 56 . Thus, these data suggest that inhib ition of ceramide metabolism, at least via targeting ceramide trafficking by CERT, might provide novel strat egies for inducing cancer cell death or attenuating drug resistance. However, it remains to be elucidated whether SMS inhibition has direct roles in inducing cell death or drug sensitivity in cancer cells or tumours.
CERK and GCS. CERK phosphorylates ceramide to generate C1P, which induces eicosanoid synthesis and cell migration via the activation of cytosolic phospho lipase A2α (cPLA2α) 57 . Increased CERK-C1P signal ling promoted breast cancer cell survival and mammary tumour recurrence following HER2 inhibition in mouse models 58 . Moreover, a CERK inhibitor, NVP231, inhib ited breast and lung cancer cell proliferation by inducing ceramidemediated cell cycle arrest and apoptosis 59 . Ceramide can also be utilized by GCS as a pre cursor for glucosylceramide generation. In fact, GCS expression was associated with poor prognosis in patients with oral cavity cancers 60 . Molecular or phar macological inhibition of GCS attenuated resistance to chemotherapeutic drugs in head and neck cancer or hepatocellular carcinoma cells 61, 62 . In addition, inhibition of GCS restored p53dependent apopto sis, which was reported to be ceramidedependent, in ovarian cancer cells expressing mutant p53 (REF. 63 ). GCSdependent accumulation of glucosylceramide, the precursor for complex glycosphingolipid synthesis, was required for the maintenance of breast cancer stem cell (CD44
) pluripotency, which might be associated with accumulation of glycosphingolipids such as globotriosylceramide (Gb3), which are known markers of stem cells 64 . These findings suggest that both CERK and GCS are key therapeutic targets for indu cing ceramidemediated cancer cell death or reversal of resistance to apoptosis.
CDases. There are three classes of CDases -acid, neutral and alkaline. AC 65 was found to be upregulated in various cancer types, notably prostate cancer 66, 67 . Radiationinduced AC expression was reported to mediate resistance to radiation therapy, resulting in pros tate tumour relapse in mouse models, consistent with the observation of increased AC expression levels in tumour samples from patients with prostate cancer who had relapsed after radiation therapy 66 . Furthermore, AC promoted chromosome region maintenance 1 protein homologue (CRM1; also known as EXP1)dependent nuclear export of PTEN through S1Pmediated AKT signalling in prostate cancer cells 67 . Moreover, a positive feedback mechanism was reported between CERS6 and AC activation, whereby induction of CERS6 expression increased AC expression through activation of JUN Nterminal kinase (JNK) in colon cancer cells 68 . Thus, these studies indicate that AC mediates the metabolic communication between ceramide catabolism and S1P synthesis to activate prosurvival S1P signalling in cancer cells. However, it remains unknown whether ACmediated CERS6-C16 ceramide signalling induces colon cancer cell survival by inhibiting ATF6 and inducing ER stress.
Neutral ceramidase 69 (NCDase) utilizes ceramide for sphingosine release, which is then utilized for S1P biosynthesis by SPHK1 and/or SPHK2, resulting in the inhibition of cell death through reduced levels of proapoptotic ceramide. NCDase is highly abun dant in intestinal tissues, and inhibition of NCDase resulted in ceramidemediated apoptosis and autophagy
Hexosylceramides
Ceramide molecules that contain a hexosyl group, such as monohexosylceramide (glucosylceramide).
Necroptosis
A programmed necrosis involving receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and RIPK3 signalling that ruptures the plasma membrane, leading to cellular rupture and death.
Mitochondrial outer membrane permeabilization (MOMP) . A key step in the execution of apoptosis, regulated by BCL-2 family member proteins, that leads to the release of pro-cell death factors, such as cytochrome c, from the internal mitochondrial membrane to engage with caspase signalling.
in colon cancer cells and tumour xenograft mouse models 70 . Moreover, NCDasenull mice were protected from the development of AOMinduced colon cancer 70 . There are three alkaline CDases (alkaline cera midase 1 (ACER1), ACER2 and ACER3), which also hydrolyse ceramide to sphingosine. Although the role of ACER1 (REF. 71) in cancer is currently unknown, acti vation of ACER2 increased cancer cell death in response to doxorubicininduced DNA damage owing to sphin gosine accumulation and reactive oxygen species sig nalling, despite a reduction in ceramide generation 72 . ACER3 selectively catabolizes C18:1 ceramides and C20:1 ceramides, which contain unsaturated forms of C18 and C20 fatty acids such as oleic acid or paullinic acid, respectively, whereas conventional C18 ceramide and C20 ceramide contain saturated fatty acids such as stearic acid or arachidic acid, respectively. In mice, defi ciency in ACER3 exacerbated the development of coli tis and colitisassociated CRCs, and these Acer3 −/− mice exhibited increased systemic inflammation and a hyper active innate immune system owing to the accumulation of lactosylceramides and monohexosylceramides 73 . These studies collectively suggest that, in addition to conventional ceramides, accumulation of com plex sphingolipids (such as lactosylceramides and exosylceramides (BOX 1)) due to alterations in CDase expression and/or activity influences cancer cell death versus survival. Accordingly, it will be important to control for and monitor the accumulation of various classes of sphingolipids while targeting these metabolic enzymes for cancer therapy. SPHK1 and SPHK2. SPHK1 and SPHK2 belong to the diacylglycerol kinase family and mediate the genera tion of S1P from ceramide (FIG. 1) . SPHK1 is localized predominantly in the cytosol and is detected in mice at embryonic day 7 (E7) of development, whereas SPHK2 is localized mainly in the nuclear membrane and also in the cytoplasm and is expressed at E11 (REF. 74 ), indicat ing their distinct biological roles and utility as different downstream signalling targets in cancer despite their metabolic redundancy for S1P generation. For example, SPHK1 (REF. 75 ) was found to be overexpressed in various tumours, including colon cancers, and Sphk1 −/− mice that were exposed to AOM developed fewer colon tumours than Sphk1 wildtype mice 76 . In a meta analysis of clin ical studies, increased expression of SPHK1 mRNA was indicative of poor prognosis and decreased survival in patients with various cancers 77 . Moreover, the long noncoding RNA Khps1, which is regulated by the tran scription factor E2F1, was found to be transcribed in an antisense orientation to SPHK1 and induced SPHK1 expression via recruitment of histone acetyltransferase p300-CREBbinding protein (CBP) and E2F1 to the SPHK1 promoter 78 . Similar to SPHK1, tumours from patients with non smallcell lung cancer exhibited increased levels of SPHK2 compared with matched normal tissues, and high SPHK2 expression was associated with resistance to gefitinib and lower overall survival (OS) compared with patients who had low SPHK2 expression 79 . In vitro, CRC cell proliferation was induced by SPHK2 overexpression owing to increased MYC signalling 80 . Moreover, epider mal growth factor (EGF)mediated phosphorylation of SPHK2 (at Ser351 and Thr578) by ERK1 stimulated the migration of breast cancer cells towards EGF 81 . Thus, the findings of these studies suggest that both SPHK1 and SPHK2 have important roles in inducing cancer cell survival, supporting the importance of sub cellular localization of S1P generation in determining the activation of specific oncogenic signalling pathways.
SPL and SGPPs. SPL activity provides an exit route from sphingolipid metabolism via the rapid hydrolysis of S1P. SPL was downregulated at the protein level in colon cancer tissues, and SPL silencing promoted colon car cinogenesis through signal transducer and activator of transcription 3 (STAT3)mediated miR181b1 expres sion, which occurred via S1P accumulation and/or S1PR signalling 82 . By contrast, reconstitution of SPL by over expression increased p53dependent and p38 dependent apoptosis owing to reduced S1P signalling in colon cancer cells and xenograft tumours 83 . Inhibition of SGPP1, which increases S1P accumulation, promoted gastric cancer cell migration 84 . Moreover, SGPP1 over expression, indicative of reduced S1P signalling, in patients with gas tric cancer was associated with improved OS compared with patients with low SGPP1 expression 84 . Thus, these studies suggest that activation of SPL and/or SGPP1 (and possibly SGPP2) would provide a novel anticancer therapeutic strategy (TABLE 1) .
Sphingolipids in cancer cell death
The synthesis and/or accumulation of ceramide in response to cellular stress is known to mediate cancer cell death through various mechanisms, including induction of apoptosis, necroptosis, autophagy and ER stress. These ceramidemediated cell death pathways are differentially regulated based on cell and/or tissue type, the subcellular localization of ceramide and/or the availability of downstream targets of ceramide.
Apoptosis
It was initially demonstrated that ceramide induces apoptosis (BOX 2) in leukaemic cells 85 . The roles of cera mide biogenesis in radiationinduced apoptosis were later revealed, which involved ceramiderich macro domains on the mitochondrial membrane that are required for BAX integration in HeLa cells 37, 86 (FIG. 2) .
The involvement of ceramide channels in the induction of mitochondrial apoptosis through mitochondrial outer membrane permeabilization (MOMP) was reported as a possible mechanism, at least for radiationinduced apop tosis 87 . NSMasedependent sphingolipid metabolism promoted MOMP via coordinated activation of BAX and BAK, suggesting that BCL2 homology 3 (BH3)only proteins and the specific sphingolipid milieu at the mito chondrial membrane regulate apoptosis 88 . Moreover, silencing of the gene encoding lysosomalassociated transmembrane protein 4B (LAPTM4B) -which facili tates removal of ceramide from late endosomal (LE) organelles -induced sphingolipid accumulation in LE 
Survival autophagy
A type of macroautophagy that mediates a vacuolar and self-digesting mechanism responsible for the removal of damaged proteins and/or organelles by doublemembraned autophagosomes associated with lysosomes, providing nutrients for cell survival during stress conditions such as starvation.
Mitochondrial fission
The partition of the mitochondrial membrane between two forming daughter mitochondria, which is regulated by a set of proteins including dynamin-related protein 1 (DRP1), parkin and PTEN-induced putative kinase 1 (PINK1).
organelles, destabilized the lysosomal membrane and resulted in resistance to caspase 3 activation and apopto sis induced by chemotherapeutic drugs in A431 human epidermoid carcinoma cells 89 (FIG. 2) . This study suggests that subcellular compartmentalization of ceramide by LAPTM4B regulates sphingolipidmediated caspase 3 activation and apoptosis.
Necroptosis
Induction of ceramide signalling was shown to be involved in necroptosis in response to ceramide expo sure, to CERS1 overexpression and consequent C18 ceramide generation (possibly in the ER) and to treat ment with the sphingosine analogue drug FTY720, also known as fingolomod (Gilenya; Novartis) in human lung cancer cells [90] [91] [92] (FIG. 2) . Interaction of ceramide or FTY720, but not phosphorylated FTY720 (PFTY720), with phosphatase 2A inhibitor I2PP2A (also known as SET) activated the tumour suppressor serine/threonine protein phosphatase 2A (PP2A) 90, 91 , inducing necropto sis and growth suppression in lung tumour xenograft models, which was mediated by receptor interacting serine/threonineprotein kinase 1 (RIPK1) kinase activity 91, 92 (FIG. 2) . The involvement of direct activa tion of RIPK1 by PP2A and/or ceramide generation in FTY720dependent necroptosis, however, is unclear and should be investigated in future studies.
Autophagy
The accumulation of dihydroceramide and ceramide induces autophagy, resulting in contextdependent cancer cell death or survival 93 . Tetrahydrocannabinol, a psychotropic cannabinoid (an active constituent of cannabis), triggered dihydroceramide accumulation in the ER of glioma cells, which promoted permeabiliza tion of the autophagosomal and lysosomal membranes, resulting in cathepsin release and apoptotic cell death (FIG. 2) , possibly via its conversion to ceramide by DES 94 . Accumulation of sphingomyelin (by silencing of SMPD1) in cancer cells led to the accumulation of elon gated and unclosed autophagosomal membranes with reduced association of autophagyrelated protein 9A (ATG9A) (FIG. 2) , suggesting a negative role for sphingo myelin in the maturation of early autophagosomal membranes through alterations in ATG9A trafficking 95 . A pivotal study demonstrated that the induction of ceramide stress using chemotherapeutic agents or exogenous ceramides promoted accumulation of CERS1generated C18 ceramide at the outer mitochon drial membrane, leading to the recruitment of auto phago somes to mitochondria via interaction of ceramide with LC3BII (formed by lipidation of microtubule associated protein 1 light chain 3β (LC3B)) 96 . This then selectively induced mitophagy and cell death in head and neck cancer 96 and acute myeloid leukaemia (AML) cells 97 (FIG. 2) . Nutrient deprivation, which induces survival autophagy, had no effect on ceramideinduced lethal autophagy or mitophagy in head and neck cancer cells 96 , suggesting that induction of selective mitophagy, but not general autophagy, mediates cancer cell death in head and neck cancer and AML cells both in culture and in mouse models. It was also shown that ceramide dependent lethal mitophagy is regulated by the activa tion of dynaminrelated protein 1 (DRP1) (FIG. 2) and mitochondrial fission, which involved protein kinase A (PKA) inhibition and decreased phosphorylation of DRP1 at Ser637 in Fmslike tyrosine kinase 3 (FLT3) positive AML cells in culture and in AML blasts obtained from patients and grown in the bone marrow of immuno compromised mice 97 . These findings therefore indicate that CERS1generated ceramide acts as a receptor on the mitochondrial membrane for LC3Bcontaining auto phago somes to induce selective and lethal mitophagy in head and neck cancer and AML cells.
ER stress and cell cycle arrest
Induction of ceramideassociated ER stress was reported as an upstream regulator of autophagy in glioma cells 98 . Additionally, doxorubicin treatment elevated ceramide levels, which activated calpainmediated ATG5 cleavage, switching from protective ER stress and autophagy to ceramidemediated apoptosis in SGPP1depleted cells 99 . Moreover, methotrexateinduced folate stress increased the formation of ER stress aggregates enriched with CERS6, which was associated with the activation of p53 in lung cancer cells 100 . Thus, ceramide signalling might be involved in the induction of ER stress, although CERS6generated C16 ceramide seems to protect against this process, at least in oral cancers 41, 42 . Deletion of Sphk1 in Tp53null mice attenuated for mation of thymic lymphomas, which was accompanied by elevation of ceramide levels, increased expression of cell cycle inhibitors and tumour cell senescence 101 . Endogenous ceramides, which were generated via the sal vage pathway in response to C6 ceramide exposure, inter acted with phosphatidylinositol 3kinase C2β (PI3KC2β) and suppressed its activation, resulting in the inhibition
Box 2 | Ceramide -a bona fide inducer of apoptosis
In 1993, the induction of apoptosis by ceramide was first demonstrated in leukaemic cells by treatment with exogenous ceramide 85 . Since then, there have been myriad studies showing that endogenously generated ceramide is a bona fide inducer of apoptosis that is regulated by various mechanisms in a cell-type-dependent and/or context-dependent manner (as discussed in the main text) 36, 37, 86, 89 . However, there are also studies that have demonstrated that induction of ceramide might protect some cancer cells from cell death. For example, ceramide synthase 6 (CERS6)-generated C16 ceramide was shown to be important in protecting head and neck squamous cell carcinoma (HNSCC) cells from endoplasmic reticulum (ER) stress-mediated apoptosis 41, 42 . This observation was consistent with other studies, which reported that ceramide synthase HYL-2, which generates C20 ceramide and C22 ceramide, protected Caenorhabditis elegans from anoxia-induced death 175 . Moreover, studies in HeLa cells revealed that overexpression of CERS2, which increased the generation of C24 ceramide, protected cells from ionizing radiation (IR)-induced apoptosis, whereas C16 ceramide generated by CERS5 and CERS6 was responsible for IR-mediated apoptosis in these cells 176, 131 . Overall, these studies suggest that although ceramide mediates apoptosis in the majority of cancer cells via mitochondrial membrane perturbation and/or influencing cell death signalling, it might also have protective roles against apoptosis depending on the presence and/or absence of downstream ceramide targets, the subcellular localization of ceramide and the types of stress stimuli. As mechanisms of ceramide-mediated apoptosis and signalling pathways are elucidated in greater detail, the question of how these differential roles of ceramide in inducing apoptosis versus protection from apoptosis in cancer cells are regulated will be addressed in future studies.
of ovarian cancer cell motility in response to EGF stimu lation in culture and attenuation of peritoneal tumour metastasis of human ovarian cancer xenografts in mice 102 . Together, these studies suggest that the distinct sub cellular compartmentalization and/or trafficking of sphingolipids and their various downstream targets, especially ceramides with different fatty acyl chains, dic tate their roles and mechanisms of action for induction of cancer cell death and/or growth inhibition.
S1P in cancer growth and metastasis
The metabolic conversion of ceramide to S1P by the functions of SPHK1 and SPHK2 mediate cancer growth and metastasis via S1PRdependent or S1PR independent signalling. Interestingly, signal trans duction pathways mediated by S1P through selective S1PR1-5 signalling have distinct roles in the regu lation of cancer cell proliferation, migration and/or invasion in a contextdependent manner. Moreover, downstream Nature Reviews | Cancer In response to cellular stress, the increased generation of ceramide (Cer) via (dihydro)ceramide synthases (CERS1-6) and sphingomyelinases (SMases) results in cancer cell death and tumour suppression, which is regulated by various mechanisms involving both direct and indirect targets of ceramide. Ceramide accumulation in the mitochondrial membrane induces BAX recruitment to the mitochondria, resulting in mitochondrial outer membrane permeabilization (MOMP), caspase activation and apoptosis in response to radiation [86] [87] [88] . In addition, regulation of ceramide transport from late endosomal organelles by lysosomal-associated transmembrane protein 4B (LAPTM4B) stabilizes lysosomal membranes, leading to ceramide-mediated caspase 3 activation and apoptosis induced by chemotherapeutic drugs 89 . Activation of serine/ threonine-protein phosphatase 2A (PP2A) is mediated by direct binding between phosphatase 2A inhibitor I2PP2A and ceramide or FTY720, a sphingosine analogue drug, leading to receptor-interacting serine/threonine-protein kinase 1 (RIPK1)-dependent necroptosis in lung cancer cells 91 . Cellular stress in response to chemotherapy results in C18 ceramide trafficking to the outer mitochondrial membrane, which then directly binds the lipidated form of microtubuleassociated protein 1 light chain 3β (LC3B-II) to recruit autophagosomes to mediate lethal mitophagy by the activation of dynamin-related protein 1 (DRP1) and mitochondrial fission 96, 97 . Autophagy in cancer cells has been shown to be induced by accumulation of dihydroceramide and/or ceramide in the endoplasmic reticulum (ER) of glioma cells in response to tetrahydrocannabinol, a psychotropic cannabinoid. Accumulation of dihydroceramide and/or ceramide in the ER leads to permeabilization of the autophagosomal and lysosomal membranes, resulting in cathepsin release and apoptotic cell death 94 . Moreover, hydrolysis of sphingomyelin (SM) to generate ceramide via acid sphingomyelinase (ASMase) is important to promote the elongation and maturation of autophagosomal membranes via recruitment of autophagy-related protein 9A (ATG9A), suggesting a novel role for ceramide in the maturation of early autophagosomal membranes 95 .
Lymphopaenia
A condition defined by the presence of abnormally low levels of lymphocytes (white blood cells or immune cells) in the blood.
signalling targets of S1P generated by SPHK1 versus SPHK2 independent of S1PR involvement seem to be distinct.
Pro-survival S1P-S1PR signalling
The recruitment and activation of SPHK1 at the plasma membrane leads to S1P generation and the subsequent engagement of S1P with its specific receptors, S1PR1-5, therefore activating oncogenic sphingolipid signalling in an autocrine or paracrine manner 103 (FIG. 3) .
S1P.
Oestradiol was reported to mediate export of S1P from breast cancer cells via ATPbinding cassette subfamily C member 1 (ABCC1) and ATPbinding cassette subfamily G member 2 (ABCG2), leading to S1PR signalling and cell growth and survival 104 (FIG. 3) .
Protein spinster homologue 2 (SPNS2) selectively mediates S1P secretion in endothelial cells, but not in erythrocytes or platelets 105 (FIG. 3) . Interestingly, dele tion of Spns2 resulted in a marked reduction in lung metastasis after tail vein injections of various types of mouse cancer cells and was associated with circulating lymphopaenia and increased infiltration of T cells and natural killer cells to the lungs, therefore enhancing tumour cell killing and decreasing metastatic burden in Spns2 −/− mice 106 . These data were consistent with a study reporting the systemic roles of S1P as a transducer of host-cancer cell communication to induce metasta sis of mouse bladder cancer or melanoma cells to the lungs of Sphk1 +/+ control mice, which was reduced in Sphk1 −/− mice 107 . The S1Pmediated host-cancer cell communication occurred by S1PR2dependent repres sion of breast cancer metastasissuppressor 1 (BRMS1), a master suppressor of tumour metastasis, regardless Nature Reviews | Cancer Figure 3 | Oncogenic S1P-S1PR1-5 signalling. a | Sphingosine kinase 1 (SPHK1)-generated sphingosine-1-phosphate (S1P) engages with G protein-coupled S1P receptors (S1PR1-5) to elicit oncogenic signalling 103 . S1P is secreted from cancer cells by ATP-binding cassette sub-family C member 1 (ABCC1), ATP-binding cassette sub-family G member 2 (ABCG2) 104 or protein spinster homologue 2 (SPNS2) 105 , the latter of which is active selectively in endothelial cells, leading to autocrine or paracrine signalling. S1PR signalling inhibits apoptosis, induces cell proliferation and/or migration and increases drug resistance via inhibition of BAX-caspase 3 signalling, induction of survival autophagy and/or inhibition of serine/threonine-protein phosphatase 2A (PP2A) 104, 105, 136 . b | Circulating S1P increases tumour metastasis [106] [107] [108] [109] [110] . For example, SPNS2-dependent S1P secretion from endothelial cells attenuates cytotoxic T cell function, possibly by influencing S1PR functions on immune cells 106 and/or cancer cells 107 , and therefore promotes tumour metastasis 106, 107 . Moreover, secretion of SPHK1-generated S1P from host lymphoid or vascular endothelial cells activates S1PR2 signalling in tumour cells, which inhibits expression of breast cancer metastasis-suppressor 1 (BRMS1), a master suppressor of metastasis, leading to increased metastasis 107 . Mice deficient in SPNS2 or SPHK1 exhibited reduced lung colonization and metastasis regardless of tumour levels of S1P, suggesting a role for systemic S1P in the communication between host immune cells and cancer cells to increase tumour metastasis. Inhibition of systemic S1P (using sonepcizumab; also known as Sphingomab) or S1PR2 in cancer cells (using JTE013) 107 and/or S1PR1 in cancer cells (using FTY720) 109 should attenuate metastasis. SPH, sphingosine.
of the Sphk1 and/or Sphk2 status of tumours 107 (FIG. 4) .
Moreover, attenuation of systemic S1P signalling in Sphk1 −/− mice, or using the antiS1P antibody sonep cizumab (Sphingomab; Lpath Therapeutics) 108 in Sphk1 wildtype mice, reactivated BRMS1 and inhibited lung colonization and metastasis of bladder cancer and mel anoma cancer allografts 107 (FIG. 4) . In addition, increased systemic S1P levels in Sphk2knockout mice exacerbated chronic intestinal inflammation and led to the develop ment of colitis associated cancer (CAC) via S1PR1-nuclear factorκB (NFκB)-interleukin6 (IL6)-STAT3 signalling 109 . Inhibition of S1PR1 signalling using the prodrug FTY720 attenuated CAC development in mice 109 (FIG. 4) . Moreover, osteoblastderived systemic S1P also induced proliferation and docetaxel resistance in bone metastasisderived prostate cancer cells 110 . Thus, these data suggest a key role for systemic S1P signalling in regulation of tumour growth and/or metastasis, in part by inducing S1PR signalling in tumour cells. S1PR1-5. S1PR1 was identified as potential target to block STAT3 signalling in activated B celllike dif fuse large B cell lymphoma 111 . Furthermore, elevated S1PR1 signalling in T lymphoblastic lymphoma cells was associ ated with the blockade of intravasation and haematological dissemination owing to increased inter cellular adhesion molecule 1 (ICAM1) expression and augmented cell-cell adhesion 112 .
In tumour cells, S1PR2 signalling induced AML growth and/or proliferation 113 and was shown to activate ezrin-radixin-moesin (ERM) proteins to induce motility and invasion of HeLa cells in culture 114 , consistent with S1PR2mediated tumour metastasis of bladder cancer and melanoma cells in mouse models 107 . By contrast, systemic S1PR2 signalling, mainly in endothelial cells and bonemarrowderived cells (BMDCs), was reported to inhibit tumour angiogenesis in mouse models 115 . Thus, these data suggest that targeting S1PR2 selectively in cancer cells, at least in AML, melanoma and bladder or cervical cancers, but not in normal ECs and BMDCs, provides a potential anticancer therapeutic strategy. S1PR3 signalling promoted the expansion of alde hyde dehydrogenase (ALDH)positive cancer stem cells (CSCs) via ligandindependent Notch activa tion in response to stimulation with exogenous S1P 116 ; CSCs overexpressing SPHK1 induced tumour growth in xenograft mouse models, which was mitigated by S1PR3 knockdown, and mammospheres derived from patients with breast cancer were found to contain both SPHK + ALDH1 + cells and S1PR3 + ALDH1 + cells. However, it is unknown whether S1P-S1PR3 signal ling promotes stem cell characteristics in cancer cells. Additionally, activation of S1PR3 by transforming growth factorβ (TGFβ)-SMAD3 signalling was shown to induce lung cancer progression and metastasis in a mouse model 117 . Nature Reviews | Cancer Figure 4 | Receptor-independent intracellular S1P signalling. Sphingosine kinase 1 (SPHK1)-generated sphingosine-1-phosphate (S1P) binds TNF receptor-associated factor 2 (TRAF2) to induce polyubiquitylation of receptorinteracting serine/threonine-protein kinase 1 (RIPK1), which then indirectly mediates nuclear factor-κB (NF-κB) activation 121 . S1P also directly associates with peroxisome proliferator-activated receptor-γ (PPARγ), which then mediates the recruitment of PPARγ co-activator 1β (PGC1β) to induce PPARγ-dependent gene expression and neo-angiogenesis 124 . Generation of S1P by SPHK2, which is localized in the nuclear membrane 127 , binds to histone deacetylase 1 (HDAC1) and HDAC2 and inhibits their activity at the nuclear membrane to induce epigenetic regulation of expression of CDKN1A, which encodes p21, and FOS, which encodes proto-oncogene FOS 125 . SPHK2-generated S1P also binds prohibitin 2 (PHB2) on the mitochondrial membrane to induce cytochrome c oxidase (complex IV) activity and mitochondrial respiration 126 . Generation of S1P in the nuclear envelope by SPHK2 results in S1P-telomerase reverse transcriptase (TERT) binding at the nuclear membrane, which then protects telomerase from E3 ubiquitin-protein ligase makorin 1 (MKRN1)-dependent ubiquitylation and degradation, therefore stabilizing telomerase and attenuating senescence induction 127 . This process is mediated by mimicking of TERT phosphorylation upon S1P-TERT binding, and SPHK2 knockdown, genetic loss or pharmacological inhibition using ABC294640 results in rapid telomerase degradation, leading to accelerated senescence and tumour suppression 127 . SPH, sphingosine; Ub, ubiquitin.
Gastrointestinal radiation syndrome
A syndrome caused by exposure to high doses of radiation that induces substantial cell death in the gastrointestinal tract.
In a clinical study, increased S1PR4 expression was associated with shorter diseasefree survival in a cohort of 140 patients with oestrogen receptor (ER)negative breast cancer 118 . A subsequent study demonstrated that SPHK2generated S1P induces S1PR4 signalling, preventing the nuclear translocation of S1PR2 to pro mote the growth of ERnegative breast cancer cells 119 . However, the mechanism of how S1PR4 regulates nuclear translocation of S1PR2, and the nuclear sig nalling roles of S1PR2 in ERnegative breast cancer cell growth suppression, remain unknown. Nevertheless, this mechanism appears to be cell type and/or con textdependent, as there are multiple reports suggesting that S1PR2 signalling promotes tumour growth and/or metastasis in various other cancer types, such as AML, melanoma and bladder or cervical cancers 107, [113] [114] [115] A study from 2017 demonstrated that S1P-S1PR5 signalling promoted mitotic progression in HeLa cells, leading to chromosome segregation defects 120 . Mechanistically, S1P was secreted through SPNS2 and stimulated mitosis via S1PR5dependent activation of the PI3K-AKT pathway, which required the activation of Pololike kinase 1 (PLK1) 120 . Overall, these data suggest that the selective tar geting of S1PR1-5 signalling in various cancer types is efficacious to impede S1Pmediated cancer growth, proliferation and/or metastasis.
S1PR-independent S1P signalling
In addition to receptordependent signalling func tions, endogenous S1P also regulates cancer cell sig nalling without S1PR involvement. For example, SPHK1generated S1P directly binds to the ubiquitin ligase TNF receptorassociated factor 2 (TRAF2) in the cytoplasm, inducing Lys63polyubiquitylation of RIPK1, phosphorylation of inhibitor of NFκB kinase (IKK) and degradation of inhibitor of NFκB (IκB), there fore activating NFκB signalling in HEK293 and HeLa cells 121 . This, however, seems to be context dependent, as SPHK1generated S1P was not required for NFκB acti vation and inflammation in macrophages 122 or keratino cytes 123 . Moreover, SPHK1generated S1P was reported as a ligand for peroxisome proliferator activated receptorγ (PPARγ) that regulates neoangiogenesis in human endothelial cells, possibly by influencing tran scription of PPARγresponsive genes 124 , consistent with the roles of S1P in inducing tumour angiogenesis and/or metastasis (FIG. 4) .
SPHK2generated nuclear S1P bound directly to HDAC1 and HDAC2, inhibiting their enzymatic activity and therefore preventing deacetylation of histone H3 in human MCF7 breast cancer cells 125 . The S1P-HDAC1-HDAC2 repressor complex reportedly associated with the promoter regions of CDKN1A, which encodes p21, and FOS, which encodes protooncogene FOS, inducing their expression 125 (FIG. 4) . It remains unknown, however, whether SPHK2-S1Pmediated inhibition of HDAC1 and HDAC2 alters gene expression globally in cancer cells to promote or suppress tumour growth. In another study, SPHK2generated S1P in mitochondria associ ated with prohibitin 2 (PHB2) to induce cytochrome c oxidase (complex IV) function and mitochondrial respi ration 126 . In addition, SPHK2derived S1P in the nuclear envelope directly interacted with telomerase reverse transcriptase (TERT), the catalytic subunit of telomer ase, to prevent E3 ubiquitinprotein ligase makorin 1 (MKRN1)dependent ubiquitylation and degradation of TERT, therefore inhibiting telomere damage and senescence 127 . Interestingly, S1P binding to TERT at the nuclear membrane mimicked TERT phosphorylation without protein kinase function, therefore regulating TERT stability at the nuclear envelope 127 . Inhibition of SPHK2 resulted in the rapid degradation of TERT, inducing severe telomere damage and rapid senescence, leading to cancer growth suppression 127 (FIG. 4) .
Thus, these data suggest that SPHK1generated and SPHK2generated S1P have distinct endogenous tar gets, regulating TRAF2 and PPARγ (SPHK1generated S1P) versus HDAC1, HDAC2, PHB2 and telomerase (SPHK2generated S1P) through sphingolipid-protein interactions independent of S1PR signalling.
Sphingolipids and cancer therapy
Cellular stress induced by chemotherapeutic agents and/or radiation is known to induce procell death mech anisms and tumour suppression, at least in part through the induction of ceramide generation. Conversely, chan nelling ceramide for S1P generation results in resistance to chemotherapy and radiotherapy. Moreover, there have been new developments in understanding the roles of sphingolipids in the regulation of immune cell function in the context of cancer immunotherapy.
Chemotherapy and radiotherapy
Ceramide generated de novo was shown to mediate daunorubicininduced apoptosis in human p388 leu kaemia and U937 histiocytic lymphoma cells 128 . In a phase II clinical trial, elevated serum levels of C18 cera mide were markedly associated with improved response to gemcitabine plus doxorubicin combination therapy in patients with recurrent head and neck cancers 129 , a combination that induced CERS1dependent C18 ceramide generation in HNSCC cells and xenograft tumour models in mice 130 . Ceramide biogenesis at the mitochondrial membrane by activation of CERS func tion was required for radiationinduced apoptosis in the germ line of Caenorhabditis elegans via activation of CEP1 (the worm homologue of p53) and BH3domain protein EGL1-CED3 caspase 131 . Interestingly, abro gation of ceramide signalling using an anticeramide neutralizing antibody prevented gastrointestinal dam age in response to high doses of radiation, relieving gastrointestinal radiation syndrome associated mortality in mouse models 132 . However, it remains unknown whether an anticeramide antibody can also protect against endothelial cell apoptosis in the small intesti nal lamina propria and crypt stem cell clonogens dur ing anticancer radiotherapy. Thus, these data suggest that ceramide generation in cancer cells in response to chemotherapy and radiotherapy has an important role in tumour suppression. However, radiationinduced cera mide might also exert gastrointestinal toxicity through induction of intestinal stem cell death, which needs to be controlled to reduce general adverse effects of radiation therapy.
Drug resistance
The conversion of ceramide to glucosylceramide by GCS has been shown to mediate drug resistance in various cancers 133 . For example, doxorubicin treatment increased GCS expression in invasive ductal breast cancer cells through recruitment of transcription fac tor Sp1 (SP1) to the GCS (also known as UGCG) pro moter 134 . Similarly, SPHK1 overexpression was reported at intrinsic or acquired resistance to cetuximab in CRC cell lines, xenograft mouse models and tumours obtained from patients 135 . Interestingly, S1PR1 inhib ition using FTY720 sensitized resistant CRC cells and tumours to cetuximab 135 . In addition, overexpression of SPHK1 induced resistance to imatinibmediated apoptosis in chronic myeloid leukaemia (CML) cells via inhibition of PP2A signalling through S1PR2 activa tion 136 . Moreover, miR95mediated silencing of SGPP1 promoted S1Pdependent resistance to radi ation in mouse models of breast and prostate tumours 137 . Thus, increased sphingolipid metabolism towards glucosyl ceramide and/or S1P generation results in resistance to anticancer therapy. Hence, while GCS and SPHK1/2 are potential therapeutic targets to overcome drug resist ance, increased accumulation of their sphingolipid products -glucosylceramide and S1P, respectively -might be potential predictive biomarkers for chemotherapy resistance in various cancers.
Tumour immunology and immunotherapy
The roles of S1P-S1PR signalling in the induction of immune cell egress from lymphoid organs to the blood has been established 138 . Many studies suggest that sphingo lipids also regulate the antitumour functions of various immune cell types. For example, ceramide inhibited the function of myeloidderived suppressor cells (which normally inhibit cytotoxic T lymphocytes) by activation of lysosomal cathepsin B and cathepsin D, leading to attenuation of autophagy and induction of ER stress, therefore enhancing cytotoxic T lymphocyte function and suppression of CMS4metderived soft tissue sarcoma tumour growth in mouse models 139 . In patients with Gaucher disease, who are susceptible to developing myeloma 25 , clonal immunoglobulin was reactive against lysoglucosylceramide (an acyl group derivative of glucosylceramide) owing to a deficiency in glucocerebrosidase/glucosylceramidase, which is highly elevated in these patients 140 . Interestingly, in Gaucher disease, complement signalling via complement C5a and C5a receptor 1 (C5aR1) induced the accumula tion of glucosylceramide and tissue inflammation 141 . Moreover, CERS6generated C16 ceramide increased T cell response to alloantigens during allogeneic haematopoietic stem cell transplantation (alloHSCT) in a mouse model of leukaemia, an effective immunotherapy for various haematological malignancies 142 . Interestingly, data revealed that genetic loss of CERS6 prevented devel opment of graft-versus-host disease in mouse models, a major toxic effect limiting the antileukaemic efficacy of alloHSCT 142 . In addition, αgalactosylceramide -a marinespongederived antitumour agent composed of ceramide conjugated to galactose via an αlinkage -was shown to activate natural killer cells 143 . S1P-S1PR signalling has also been associated with the regulation of immune cell function in cancer models. STAT3induced S1PR1 signalling provided a positive feedback loop for STAT3 activation in cancer cells and immune cells within the tumour micro environment to promote malignant progression 144 . Furthermore, enterobacteriasecreted particles medi ated the production of S1Pcontaining exosomelike structures by intestinal epithelial cells, which drove T helper 17 (T H 17) cellmediated development of colon cancer through activation of CCchemokine ligand 20 (CCL20), prostaglandin E2 (PGE2) and MYD88 signal ling 145 . Phosphoproteomic analysis of multiple sclero sis (MS) brain lesions revealed that phosphorylation of S1PR1 at Ser351 exacerbated T H 17 cellmediated auto immune neuroinflammation 146 . However, it remains unknown whether S1PR1 phosphorylation controls immune cell function in cancer and/or tumour suppres sion. Interestingly, S1P secretion from dying cells con stituted a 'findme signal' for macrophage recruitment, promoting erythropoietin signalling in macrophages and enhancing phagocytosis of apoptotic cells and immune tolerance 147 . Collectively, these findings suggest that ceramide and S1P metabolism have key roles in the regulation of tumour immunology and that targeting S1P signalling might be a promising strategy to improve antitumour immunotherapy.
Therapeutic targeting of sphingolipids FTY720, a sphingosine analogue drug derived from myriocin, has been successfully used to therapeuti cally target sphingolipid signalling for the treatment of patients with relapsing MS 148, 149 (TABLE 2) . The pro drug FTY720, which is phosphorylated by SPHK2 to generate PFTY720, a structural analogue of S1P but functional antagonist for S1PR1, promoted tumour suppression via S1PRdependent 109 or receptor independent 91 mechanisms in colon and lung cancer cell lines and mouse models, respectively. FTY720, but not PFTY720, inhibited CML stem cell proliferation and expansion in vitro, therefore reversing imatinib (Gleevec; Novartis) resistance 150 . Although FTY720 concentrations of 10-20 μM are required to effec tively induce cancer cell death in cell culture studies, tumour suppression in human lung cancer xenograft mouse models was achieved using physiologically rele vant concentrations of FTY720 (3 or 10 mg per kg daily) that suppressed the immune system via inhib ition of S1PR1dependent lymphocyte egress in mouse models, leading to induction of necroptosis in vivo 91, 150 . Interestingly, lipidomicsbased measurements showed that lung tumour tissues mainly accumulated the prodrug FTY720 with anticancer function, whereas serum primarily contained the immune suppressive PFTY720 after treatment with FTY720 in mice 91 . Thus, these data support that FTY720 might be considered 
Graft-versus-host disease
A medical complication that might occur after allogeneic haematopoietic stem cell transplantation, in which transplanted immune cells from a donor (graft) recognize the recipient (host) tissues as foreign (non-self), attacking the host cells and resulting in tissue or organ damage.
for anticancer therapy in various cancer settings. As PFTY720 does not seem to be involved in CML or lung cancer cell death, one future approach might be to use FTY720 in combination with an SPHK2 inhib itor (such as ABC294640 (REF. 151)), which should pre vent PFTY720 synthesis and immune suppression to improve FTY720mediated anticancer therapy.
In addition, highly soluble pyridinium ceramides (TABLE 2) , which selectively accumulate in the mito chondria of cancer cells, induced lethal mitophagy and tumour suppression in head and neck and prostate cancer cell lines and xenograft tumours in mice 152, 153 . Moreover, inhibition of survivin by nanoliposomal ceramide (NLC) resulted in the complete remission of the natural killer type of aggressive large granular lym phocytic leukaemia in cell lines and mouse models 154 (TABLE 2) . NLC is now being tested in a phase I clin ical trial for the treatment of patients with advanced solid tumours 155 .
Targeting SPHK-S1P-S1PR signalling. The pro cesses of S1P generation and signalling have also been promising targets for anticancer therapy. For exam ple, SK1I, a sphingosine analogue and competitive inhibitor of SPHK1, attenuated glioblastoma growth and/or proliferation in cell lines and xenograft models 156 .
In addition, a potent SPHK1 selective inhibitor, PF543 (REFS 157, 158) , was initially reported to lack cytotoxi city in cancer cells despite reducing S1P generation and accumulation 157 . However, recent studies have demon strated the efficacy of PF543 in inhibition of TNBC or CRC growth and/or proliferation in cell culture or in xenograft mouse models 159 . There are also S1PR1 and S1PR3 (VPC03090) 160 or S1PR2 (AB1) 161 antagonists under preclinical evalu ation (TABLE 2) , which might be tested as anticancer drugs in future clinical trials.
The antiS1P antibody sonepcizumab 108 has been evaluated in a phase II clinical trial for the treatment of patients with renal clear cell carcinoma (RCC) who were refractory to antiVEGF therapy 162 . Forty patients with RCC who had received a median of three prior therapies were recruited to this multicentre trial, and a median OS of 21.7 months was reported; however, the primary end point based on 2 month progressionfree survival was not achieved 162 . Although a limited num ber of patients (10%) exhibited a partial response with a median response duration of 5.9 months with no major toxicity, the efficacy of sonepcizumab alone in metastatic RCC was not impressive. Interestingly, biomarker focused studies showed an increase in sys temic S1P concentrations with sonepcizumab treat ment 162 , suggesting that metastatic S1P signalling was still active in patients given the therapy, which might be the reason for this limited efficacy of the drug in the clinic. Thus, future studies are needed to understand how systemic S1P induces tumour growth and metas tasis to improve the neutralization of S1P signalling using lipidspecific antibodies in patients. In addition, testing the efficacy of sonepcizumab in combination with various SPHK1 and SPHK2 inhibitors or S1PR2 antagonist to treat patients with metastatic RCC or lung cancer is warranted.
The SPHK2 inhibitor ABC294640 suppressed the growth of lung or pancreatic tumours via different mechanisms, including inhibition of telomerase stability or suppression of MYC and ribonucleoside diphosphate reductase subunit M2 (RRM2) expression 127, 163 (TABLE 2) .
It was also shown that ABC294640 has an off target effect, mediating dihydroceramide accumulation owing to DES inhibition in prostate cancer cells and tumours 164 . Nevertheless, a phase I clinical trial evalu ating ABC294640 (Yeliva; RedHill Biopharma) for the treatment of patients with solid tumours has been suc cessfully completed, which reported a rapid and biphasic reduction in plasma levels of S1P 165 . Furthermore, ABC294640 is currently being tested in a phase II clinical trial for the treatment of patients with hepato cellular carcinoma who exhibit resistance to sorafenib 166 . Moreover, targeting of SPHK2 using ABC294640 for the treatment of patients with refractory multiple mye loma 167, 168 , diffuse large B cell lymphoma 169 or Kaposi sar coma 170 is under investigation in phase Ib and phase II clinical trials.
Overall, these studies demonstrate that induction of ceramide or inhibition of S1P metabolism and/or sig nalling are novel and innovative strategies for anticancer therapy in the clinic. 
Conclusions
There have been myriad discoveries elucidating the roles and mechanisms of sphingolipids in cancer signalling during the past decade, which has required the devel opment of analytical, molecular, structural, genetic and pharmacological tools. For example, the development of a highly quantitative analytical methodology using mass spectrometry 171, 172 
to measure sphingo lipid molecules -including 1Oacylceramide 173 , d16 or d18 LCBcontaining ceramides and conventional d18 LCBcontaining ceramides and/or sphingolipids (sphingosine) 174 -in cancer cells, tissues and/or blood was key to understanding the alterations of these signal ling molecules and their metabolism in cancer versus noncancerous cells and/or tissues. Moreover, the clon ing of almost all of the key enzymes involved in sphingo lipid metabolism helped to generate genetic models to study their roles in cancer biology and/or treatment, which are now coupled with structure-functionbased anticancer drug design and development.
Mechanistically, it is well established that the sub cellular localization and downstream targets of sphingo lipids, especially ceramide and S1P, determine their distinct anticancer versus prooncogenic functions, which are dependent on context and cell type. For example, mitochondrial accumulation of ceramide, regardless of its fatty acyl composition, using pyridinium ceramide 152, 153 promoted cancer cell death by inducing mitophagy 96, 97 . Moreover, nuclear membrane localiza tion and roles of SPHK2generated S1P-protein binding increased telomerase stability and function by alloster ically mimicking protein phosphorylation 127 . These paradigms might also be important for the regulation of other S1P targets such as TRAF2 (REF. In addition, understanding the roles of sphingo lipid signalling in the regulation of communication between tumours and host cells associated with the tumour microenvironment [105] [106] [107] [108] [109] [110] , including stromal cells, endothelial cells, osteoclasts or platelets, will help to develop novel therapeutic strategies to inhibit cancer growth, proliferation and/or metastasis. Moreover, additional studies are needed to determine how sphingo lipid signalling can be altered to increase the anti tumour functions of T cells and decrease the sup pressor functions of myeloidderived suppressor cells and/or tumour associated macrophages to improve the anticancer efficacy of immunotherapy.
However, the rapid metabolic interconversions, trafficking and signalling roles within biological (organelle) membranes of sphingolipids present bio chemical and biophysical challenges for defining the roles of ceramides in the regulation of apoptosis ver sus survival 175, 176 
. Future studies are needed to determine how enzymes of sphingolipid metabolism are inter regulated, possibly by protein-protein and/or lipid-protein interactions. For this, additional molec ular and analytical tools, including antibodies with higher selectivity and/or specificity against the enzymes of sphingolipid metabolism and/or bioactive sphin golipids, should be developed. Overall, an increased understanding of the mechanisms by which sphingo lipids control cancer cell signalling and metabolism will help improve future anticancer therapy.
